Employee Loans and Share Incentive Plan - LifeTech Scientific Corporation reported a total of RMB 282,537,000 in employee loans related to the 2019 Share Incentive Plan[1] - A total of 312,620,000 shares were vested to certain employees, with 81,675,000 shares already delivered as of September 29, 2020[1] Share Acquisition - As of December 31, 2023, employees acquired all remaining 230,945,000 shares at a purchase price of HKD 1.35 per share[2]

Summary of the Conference Call Company Overview - The conference call was hosted by Huazhong Securities in collaboration with a roadshow, focusing on the listed company, Xiantian Technology [1] Key Points and Arguments - The meeting featured insights from the company's leadership, specifically from General Manager An, who shared updates on the company's recent operational status [1] Additional Important Content - The call aimed to engage with investors and provide a platform for discussing the company's strategies and performance [1]

Summary of the Conference Call Company Involved - The conference call involved **Xiantian Technology**, a publicly listed company. Core Points and Arguments - The meeting was organized by **Huazhong Securities** and included a summer strategy session, indicating a focus on current market conditions and company performance [1]. - Company leadership, specifically **Mr. An**, shared insights regarding the recent operational status of Xiantian Technology, suggesting a proactive approach to investor communication [1]. Other Important Content - The event highlights the importance of direct engagement with investors, which may enhance transparency and trust in the company's operations [1].

Summary of Conference Call Notes Company and Industry - The company is focused on developing a biodegradable iron-zinc polylactic acid stent for the treatment of coronary heart disease [1] Core Points and Arguments - **Product Advantages**: - Simple operation process with lower operational costs [1] - Strong practicality, avoiding the drawbacks of permanent metal stents [1] - Excellent quality with good degradation speed and stability, with continuous improvements in clinical products [1] - **Current Clinical Status**: - Phase II clinical trials show a higher sample lesion rate but still yield good results [1] - Phase III clinical testing is complete, with follow-up required for 1-2 months [1] - Overall effectiveness is good, significantly better than competitors [1] - **European Clinical Collaboration**: - Ongoing discussions for collaboration with a European expert for clinical trials, which may enhance effectiveness and recognition [1] - Clinical testing process remains unpredictable [1] - **Product Deficiencies**: - Rapid corrosion rate of metal iron, with plans for future improvements [1] - Slow metabolic rate of iron and polylactic acid in the human body, though not a major concern [1] Additional Important Content - **Market Entry Timeline**: - CE application for the coronary stent submitted in May, with changes in European standards (MDD to MDR) causing delays [2] - Anticipation to obtain CE certification by the end of next year in China, requiring all clinical reports and data prior to submission [2] - Currently holds 50 technical patents in China and 24-25 in Europe [2] - **Replacement Rate of Biodegradable Stents**: - Achieving comparable effectiveness to permanent stents is considered a significant victory [3] - Permanent stents are prone to fatigue and fracture, leading to higher failure rates of target vessels [3] - Biodegradable stents perform better in secondary treatments, which is a concern for permanent stents [3] - **Commercialization in Overseas Markets**: - Seeking business development partnerships to aid international expansion, particularly in Japan [4] - Confident in the European market with ongoing clinical trials, which will facilitate CE certification [4] - No immediate plans for the U.S. market due to funding constraints for clinical testing [4] - **Current Objectives**: - Successfully complete European clinical tests and follow-ups to obtain CE certification [5] - Aim for commercialization and industrialization of the product [5] - Plan to apply for CE standards in South American and BRICS countries, which are easier to obtain [5]

Financial Performance - The company reported a revenue of approximately RMB 1,267.2 million for the year ended December 31, 2023, representing a 15.5% increase from RMB 1,097.3 million in 2022[7]. - Gross profit for the same period was approximately RMB 995.6 million, up 13.9% from RMB 873.9 million in the previous year[10]. - The net profit attributable to the company's owners decreased by 19.1% to RMB 263.2 million from RMB 325.3 million in 2022[7]. - Basic earnings per share fell to RMB 0.060 from RMB 0.077, a decline of 22.1%[7]. - Operating profit increased by approximately 2.0% to about RMB 383.3 million for the year ended December 31, 2023, from RMB 375.9 million in 2022[32]. - The company recorded a net profit attributable to owners of approximately RMB 263.2 million for the year ended December 31, 2023, down about 19.1% from RMB 325.3 million in 2022[38]. - The total comprehensive income for the year was RMB 510,066,000, down from RMB 516,664,000 in 2022[183]. - The company reported a net profit for 2023 decreased to RMB 107,490 thousand from RMB 318,739 thousand in 2022, indicating a decline of 66.3%[180]. Research and Development - The company experienced a significant increase in R&D expenses, impacting overall profitability[10]. - The company plans to continue increasing R&D investment and attracting talent to enhance its innovation capabilities[11]. - Research and development expenses increased by approximately 42.9% to about RMB 297.9 million for the year ended December 31, 2023, from RMB 208.5 million in 2022[31]. - The company has accelerated product development and innovation capabilities to maintain its leading position in the industry, with several products receiving regulatory certifications, including AcuMarkTM and EpioneTM systems[18]. - The company is actively expanding its product portfolio in the structural heart disease sector, with a diverse range of offerings including left atrial appendage occluders and third-generation congenital heart disease occluders[21]. - The company plans to increase R&D investment focusing on new materials and technologies to drive product innovation and category expansion[56]. Market and Sales - Domestic sales accounted for approximately 78.3% of total revenue in 2023, down from 81.6% in 2022, while overseas sales increased by 36.0%[16]. - The company's major overseas markets in 2023 were Asia (excluding mainland China) and Europe, contributing approximately 9.0% and 8.8% to total revenue, respectively[16]. - The company anticipates an upward trend in market demand for its products driven by aging population, urbanization, and increased health awareness[51]. - The global market for left atrial appendage occluders is expected to continue expanding due to a large population of atrial fibrillation patients[52]. - The company leads the domestic market share in the provision of advanced interventional medical devices for peripheral vascular diseases[53]. - The company is the first domestic manufacturer with a complete product range of implantable cardiac pacemakers meeting international standards, with optimistic market performance expected due to unmet demand in China[54]. Assets and Liabilities - Total assets increased to RMB 4,696.4 million in 2023 from RMB 3,690.1 million in 2022[8]. - The company’s total liabilities rose to RMB 1,372.4 million in 2023, compared to RMB 769.0 million in the previous year[8]. - As of December 31, 2023, the total current assets amounted to approximately RMB 2,231.1 million, an increase of about 59.6% from RMB 1,396.7 million as of December 31, 2022[40]. - The total current liabilities as of December 31, 2023, were approximately RMB 770.1 million, up from RMB 584.7 million as of December 31, 2022[40]. - The company's equity attributable to equity holders was approximately RMB 3,370.2 million as of December 31, 2023, compared to RMB 2,900.4 million as of December 31, 2022[43]. - The company has no bank borrowings as of December 31, 2023, resulting in a debt-to-equity ratio of zero[43]. Corporate Governance - The company has adopted corporate governance principles and confirmed compliance with the corporate governance code throughout the year ending December 31, 2023, except for a deviation regarding the dual role of the chairman and CEO[67]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors as of the report date[69]. - The company is committed to reviewing and enhancing its corporate governance practices to meet the rising expectations of shareholders and investors[67]. - The company has implemented a code of conduct for securities trading that meets or exceeds the standards set forth in the listing rules[68]. - The board has established clear guidelines for management reporting to the board, ensuring accountability and transparency in decision-making[74]. - The company has established a whistleblowing policy to encourage reporting of illegal or unethical behavior[95]. Shareholder Engagement - The annual general meeting provided shareholders the opportunity to engage directly with the board regarding company performance and operations[101]. - The company has maintained a high level of transparency in its communications with shareholders and investors[100]. - The board has reviewed the implementation and effectiveness of the shareholder communication policy for the year ending December 31, 2023[100]. Employee and Management - Total employee costs, including director remuneration, amounted to approximately RMB 3,798 million for the year ended December 31, 2023, up from RMB 3,365 million in 2022[55]. - The company has expanded its board with experienced professionals, enhancing its strategic planning and business management capabilities[59][60][62]. - The management team has a strong educational background, with degrees from prestigious institutions such as Tsinghua University and Fourth Military Medical University[59][61][62]. - The company is committed to creating environmentally friendly and sustainable business operations, investing in energy-saving technologies to reduce carbon emissions[57]. Audit and Compliance - The consolidated financial statements were audited by Deloitte, and no change in auditors has occurred in the past three years[171]. - The audit committee is responsible for recommending the appointment, reappointment, and removal of external auditors to the board[93]. - The company emphasizes effective risk management and internal control systems to safeguard assets and ensure compliance with laws and regulations[83]. - The board reviews the effectiveness of the risk management and internal control systems at least annually, ensuring they are adequate and effective[94]. Future Outlook - The company recognizes the opportunities in the medical device industry will outweigh the challenges in the future, driven by factors such as aging population and rising health awareness[13]. - The company plans to continue evaluating and exploring acquisition, partnership, alliance, and licensing opportunities globally in 2024 to enhance competitiveness in existing and newly selected markets[13].

Core Insights - The company, Xianjian Technology, reported a strong revenue growth of approximately 15.5% year-on-year, reaching around RMB 1,267.2 million for the year ending December 31, 2023, with overseas sales increasing significantly by about 36.0% [1][2] - The gross profit was approximately RMB 995.6 million, reflecting a stable gross margin of about 78.6%, while the net profit attributable to shareholders was around RMB 423.3 million, with a net profit margin of approximately 33.4% [1][2] - The company maintained a robust cash position with cash and cash equivalents amounting to approximately RMB 979.3 million, a year-on-year increase of about 17.5% [1] International Business Growth - The international business segment showed strong performance, with sales contributions from overseas markets rising to about 21.7% of total revenue, particularly driven by a 52.9% growth in the European market [1][2] - The company expanded its sales channels to nearly 120 countries and regions globally, enhancing its market penetration [1][2] Domestic Market Performance - The domestic market remains the foundation of the company's operations, contributing approximately 78.3% of total revenue with a year-on-year sales growth of about 10.8% [2] - The company’s structural heart disease products, including left atrial appendage occluders and congenital heart disease occluders, recorded a revenue increase of approximately 25.6% [2] Core Business Segments - The structural heart disease segment generated approximately RMB 495.7 million in sales, with left atrial appendage occluders growing by about 32.0% year-on-year [2] - The peripheral vascular business reported revenue of approximately RMB 707.1 million, a year-on-year increase of about 9.7%, with a notable growth in stent sales [3][4] - The electrophysiology segment achieved sales of approximately RMB 64.4 million, reflecting a growth of about 10.3% [4] Innovation and R&D - The company invested approximately RMB 297.9 million in R&D, marking a year-on-year increase of about 42.9%, to enhance its technological innovation capabilities [5] - Several innovative products received regulatory approvals, including AcuMark™ and Aegisy™ systems, which are expected to drive future growth [6] Strategic Developments - The subsidiary, Yuanxin Technology, completed a strategic financing round, significantly increasing its valuation by 173%, which will support the development of its iron-based bioabsorbable materials [7][8] - The company has submitted multiple products for regulatory approval in various markets, including CE certification in Europe and NMPA approval in China [6][8] Intellectual Property and Recognition - The company has submitted a total of 2,147 patent applications, with 942 patents granted, showcasing its commitment to innovation and intellectual property protection [8] - The company received several industry awards for its innovative products, highlighting its recognition in the medical device sector [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完整性亦不發表任何聲明，並表 明不會就本公佈全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 截至二零二三年十二月三十一日止年度的 年度業績公佈 | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘 ...

2053 中 期 報 告 © Lifetach LifeTech Scientific Corporation 先 健 科 技 公 司 (於開曼群島註冊成立的有限公司) 股份代號 : 01302 目 錄 財務摘要 21 其他資料 34 35 37 38 簡明綜合現金流量表 39 2 公司資料 4 5 管理層討論與分析 19 企業管治摘要 簡明綜合損益及其他全面收益表 簡明綜合財務狀況表 簡明綜合權益變動表 簡明綜合財務報表附註 梁顯治 公司資料 於二零二三年八月三十日 | --- | --- | |--------------------------------------|---------------------------| | | | | 執行董事 | 香港股份過戶登記處 | | 謝粵輝 | 卓佳證券登記有限公司 | | （主席兼首席執行官） | 香港夏愨道 16 號 | | 劉劍雄 | 遠東金融中心 17 樓 | | （常務副總裁、首席財務官兼公司秘書） | 網站 | | 非執行董事 | www.lifetechmed.com | | 姜峰 | 股份代號 | | 獨立非執行董事 | 1302 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明 確表示，概不對因本公佈全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 截至二零二三年六月三十日止六個月 中期業績公佈 | --- | --- | |-------|--------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | ‧ | 截至二零二三年六月三十日止六個月的營業額約為人民幣 639.5 百萬元，較截至二零二二年六月三十 | | | 日止六個月的營業額約人民幣 555.2 百萬元增加約 15.2% 。截至二零二三年六月三十日止六個月的毛 | | | 利約為人民幣 504.8 百萬元，較截至二零二二年六月三十日止六個月的毛利約人民幣 441.6 百萬元增 | | | 加約 ...

() Lifetech LifeTech Scientific Corporation 先 健 科 技 公 司 (於開曼群島註冊成立的有限公司) 股份代號 : 01302 度報告 022 公司資料 2 財務概要 4 主席報告 5 管理層討論與分析 7 董事及高級管理層履歷 19 企業管治報告 23 董事會報告 39 獨立核數師報告 62 綜合財務狀況表 68 綜合權益變動表 70 綜合現金流量表 72 目錄 綜合損益及其他全面收益表 67 綜合財務報表附註 74 持作投資之物業 172 公司資料 於二零二三年三月二十九日 | --- | --- | |--------------------------------------|---------------------------------------| | | | | 執行董事 | 薪酬委員會 | | 謝粵輝 | 王皖松 （主席） | | （主席兼首席執行官） | 謝粵輝 | | 劉劍雄 | 梁顯治 | | （常務副總裁、首席財務官兼公司秘書） | | | | 香港股份過戶登記處 | | 非執行董事 | 卓佳證券登記有限公司 | | 姜峰 | 香港夏愨道 ...